A PROTAC that drives BRD4 degradation
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

A1874

Item No. 40842

Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(6S)-N-[1-[4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxyphenyl]-1-oxo-5,8,11-trioxa-2-azatridec-13-yl]-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
CAS Number
2064292-12-0
Molecular Formula
C58H62Cl3F2N9O7S
Formula Weight
1173.6
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly Soluble: 1-10 mg/mlEthanol: Slightly Soluble: 0.1-1 mg/ml
SMILES
O=C(C1=CC=C(NC([C@@H]2N[C@@H](CC(C)(C)C)[C@@](C3=CC=C(Cl)C=C3F)(C#N)[C@H]2C4=CC=CC(Cl)=C4F)=O)C(OC)=C1)NCCOCCOCCOCCNC(C[C@@H]5N=C(C6=C(N7C(C)=NN=C75)SC(C)=C6C)C8=CC=C(Cl)C=C8)=O
InChi Code
InChI=1S/C58H62Cl3F2N9O7S/c1-32-33(2)80-56-48(32)51(35-11-14-37(59)15-12-35)67-44(53-71-70-34(3)72(53)56)29-47(73)65-19-21-77-23-25-79-26-24-78-22-20-66-54(74)36-13-18-43(45(27-36)76-7)68-55(75)52-49(39-9-8-10-41(61)50(39)63)58(31-64,46(69-52)30-57(4,5)6)40-17-16-38(60)28-42(40)62/h8-18,27-28,44,46,49,52,69H,19-26,29-30H2,1-7H3,(H,65,73)(H,66,74)(H,68,75)/t44-,46-,49-,52+,58-/m0/s1
InChi Key
IPNTVOAQOGRLQB-JJMBTQCASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $59

    Add

    5 mg

    $263

    Add

    10 mg

    $467

    Add

    50 mg

    $1,021

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    A1874 is a proteolysis-targeting chimera (PROTAC) that contains (+)-JQ1 (Item No. 11187), an inhibitor of bromodomain and extra terminal domain (BET) bromodomains, conjugated to RG7388 (Item No. 21532), an inhibitor of the MDM2-p53 interaction.1 It induces the degradation of bromodomain-containing protein 4 (BRD4), decreases the levels of c-Myc, and increases the levels of p53 and p21 in HCT116 colorectal cancer cells when used at a concentration of 10 µM. A1874 (1 µM) reduces the proliferation of wild-type p53-expressing HCT116 and A375 melanoma cells but not p53 mutant-expressing NCI H2030 lung and HT-29 colon cancer cells. It decreases cell viability and induces cell cycle arrest at the G1 phase in, and reduces colony formation by, pCAN1 colon cancer cells when used at a concentration of 500 nM.2 In vivo, A1874 (20 mg/kg per day) decreases tumor volume, weight, and growth in a pCAN1 mouse xenograft model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hines, J., Lartigue, S., Dong, H., et al. MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53. Cancer Res. 79(1), (2019).

    2. Qin, A.-C., Jin, H., Song, Y., et al. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis. 11(9), 805 (2020).